Take Control of Appetite With
ENTYCE® (capromorelin oral solution).

Finally, appetite stimulation is in your control.

In the past there have been limited therapeutic options to restore appetite. That’s why Aratana Therapeutics created ENTYCE (capromorelin oral solution), the only FDA-approved veterinary therapeutic designed to safely and effectively stimulate appetite in dogs. ENTYCE works by mimicking ghrelin (the “hunger hormone”). Administered orally once a day, ENTYCE is appropriate to treat inappetence caused by chronic and acute conditions.

Why ENTYCE?

ENTYCE is the ONLY FDA-approved veterinary therapeutic labeled for stimulation of appetite in dogs and is an important tool in the clinical management of both chronic and acute conditions where appetite is reduced.

ENTYCE® (capromorelin oral solution) packaging

Inappetence Overview

Inappetence is more prevalent than you may think, with an average of 14% of U.S. canine patients presenting in clinic with the symptom each year.1

Almost any disease can manifest or develop decreased appetite (hyporexia), complete lack of appetite (anorexia) or changes in appetite (dysrexia). Inappetence can be the first sign, and may be the only sign, that a dog is sick or has an underlying health condition. Prolonged inappetence, if left untreated, can become even more detrimental to the patient than the underlying chronic or acute condition.

In addition, inappetence can represent a negative perception of the quality of life to the caregiver, which may be especially distressful and is often perceived as evidence of suffering.

1Aratana Market Research, Sept. 2015

Inappetence has three types: hyporexia (decrease in eating), dysrexia (altered patterns of eating), and anorexia (complete lack of eating)
ENTYCE® (capromorelin oral solution) mechanism of action

Mechanism of Action

ENTYCE, a ghrelin receptor agonist, is the ONLY FDA-approved veterinary therapeutic labeled for stimulation of appetite in dogs.

See how it works >

ENTYCE® (capromorelin oral solution) efficacy

Efficacy

Results from the Clinical Field Study and Laboratory Effectiveness Study demonstrated increased appetite in dogs receiving ENTYCE versus placebo.

Learn more >

ENTYCE® (capromorelin oral solution) dosing and administration

Dosing and Administration

ENTYCE provides a convenient, once-daily oral solution for treating inappetence.

Learn more >

ENTYCE® (capromorelin oral solution) side effects & safety

Safety

Results of the 12-Month Laboratory Safety Study and Clinical Field Study showed ENTYCE is well-tolerated in dogs.

Learn more >

ENTYCE® (capromorelin oral solution) Clinical References

Clinical References

Your convenient one-stop source for viewing important information.

Learn more >

ENTYCE® (capromorelin oral solution) In-Clinic Tools

In-Clinic Tools

Use these downloadable tools for identifying inappetence in dogs and how to use ENTYCE.

Learn more >

ENTYCE® (capromorelin oral solution) Professional Education

Professional Education

Find out about upcoming conferences and free webinars where you can learn more about ENTYCE.

Learn more >

IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.

Other therapeutics from Aratana

Nocita® (bupivacaine liposome injectable suspension)
NOCITA® (bupivacaine liposome injectable suspension) is the only long-acting local anesthetic that controls cranial cruciate ligament (CCL) post-op pain with one dose for up to 72 hours.

You can be sure that the local relief will help keep your patient is comfortable even after going home.

Visit Website >

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.